Cystic fibrosis drug proves effective in Real-World patients
NCT ID NCT02194881
Summary
This study followed 57 French cystic fibrosis patients with a specific genetic mutation (G551D) who took the drug Ivacaftor for at least one year. Researchers wanted to see if the drug remained effective and safe in everyday use after it was officially approved. They tracked lung function, hospital visits, and side effects to understand how the treatment worked outside of controlled clinical trials.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CYSTIC FIBROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hôpital Cochin
Paris, 75014, France
Conditions
Explore the condition pages connected to this study.